Paper36714853
C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus.
Paulowski L and 16 others. PNAS Nexus, 2022. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus. Papers, record 36714853. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36714853
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- C25-modified rifamycin derivatives with improved activity against Mycobacterium abscessus.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References66
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 27300509 | Immunosuppressive Yersinia Effector YopM Binds DEAD Box Helicase DDX3 to Control Ribosomal S6 Kinase in the Nucleus of Host Cells. | PLoS Pathog | 2016 | https://conductscience.org/library/papers/27300509 | PubMed |
| 2 | 28396540 | Rifabutin Is Active against Mycobacterium abscessus Complex. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/28396540 | PubMed |
| 3 | 8328779 | Inactivation of rifampin by Nocardia brasiliensis. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8328779 | PubMed |
| 4 | 26731090 | Biofilm Formation by Mycobacterium abscessus in a Lung Cavity. | Am J Respir Crit Care Med | 2016 | https://conductscience.org/library/papers/26731090 | PubMed |
| 5 | 21135185 | Assessment of clarithromycin susceptibility in strains belonging to the Mycobacterium abscessus group by erm(41) and rrl sequencing. | Antimicrob Agents Chemother | 2011 | https://conductscience.org/library/papers/21135185 | PubMed |
| 6 | 32651464 | Spiropiperidyl rifabutins: expanded in vitro testing against ESKAPE pathogens and select bacterial biofilms. | J Antibiot (Tokyo) | 2020 | https://conductscience.org/library/papers/32651464 | PubMed |
| 7 | 26351633 | Drug Susceptibility Testing of 31 Antimicrobial Agents on Rapidly Growing Mycobacteria Isolates from China. | Biomed Res Int | 2015 | https://conductscience.org/library/papers/26351633 | PubMed |
| 8 | 33318008 | Rifabutin Is Inactivated by Mycobacterium abscessus Arr. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/33318008 | PubMed |
| 9 | 18378709 | Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria. | Antimicrob Agents Chemother | 2008 | https://conductscience.org/library/papers/18378709 | PubMed |
| 10 | 29026882 | Efficient measurement and factorization of high-order drug interactions in Mycobacterium tuberculosis. | Sci Adv | 2017 | https://conductscience.org/library/papers/29026882 | PubMed |
| 11 | 29203492 | Extreme Drug Tolerance of Mycobacterium tuberculosis in Caseum. | Antimicrob Agents Chemother | 2018 | https://conductscience.org/library/papers/29203492 | PubMed |
| 12 | 20833823 | Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. | Am J Respir Crit Care Med | 2011 | https://conductscience.org/library/papers/20833823 | PubMed |
| 13 | 30244835 | Mode of Action of Kanglemycin A, an Ansamycin Natural Product that Is Active against Rifampicin-Resistant Mycobacterium tuberculosis. | Mol Cell | 2018 | https://conductscience.org/library/papers/30244835 | PubMed |
| 14 | 24923585 | Modification of rifamycin polyketide backbone leads to improved drug activity against rifampicin-resistant Mycobacterium tuberculosis. | J Biol Chem | 2014 | https://conductscience.org/library/papers/24923585 | PubMed |
| 15 | 29329759 | Treatment outcomes of macrolide-susceptible Mycobacterium abscessus lung disease. | Diagn Microbiol Infect Dis | 2018 | https://conductscience.org/library/papers/29329759 | PubMed |
| 16 | 22290346 | Mycobacterium abscessus: a new antibiotic nightmare. | J Antimicrob Chemother | 2012 | https://conductscience.org/library/papers/22290346 | PubMed |
| 17 | 23998761 | Identification and characterization of the genetic changes responsible for the characteristic smooth-to-rough morphotype alterations of clinically persistent Mycobacterium abscessus. | Mol Microbiol | 2013 | https://conductscience.org/library/papers/23998761 | PubMed |
| 18 | 8785251 | The clinical pharmacokinetics of rifabutin. | Clin Infect Dis | 1996 | https://conductscience.org/library/papers/8785251 | PubMed |
| 19 | 34228543 | Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus. | Antimicrob Agents Chemother | 2021 | https://conductscience.org/library/papers/34228543 | PubMed |
| 20 | 27055097 | Integration and global analysis of isothermal titration calorimetry data for studying macromolecular interactions. | Nat Protoc | 2016 | https://conductscience.org/library/papers/27055097 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42334304 | Rifamycin Structural Modifications Attenuate PXR Binding and CYP3A4 Induction. | J Med Chem | 2026 | https://conductscience.org/library/papers/42334304 | PubMed |
| 41139833 | A Multiplexed, Target-Based Phenotypic Screening Platform Using CRISPR Interference in Mycobacterium abscessus. | ACS Infect Dis | 2025 | https://conductscience.org/library/papers/41139833 | PubMed |
| 40310456 | Next-generation rifamycins for the treatment of mycobacterial infections. | Proc Natl Acad Sci U S A | 2025 | https://conductscience.org/library/papers/40310456 | PubMed |
| 40148661 | Alleviation of mycobacterial infection by impairing motility and biofilm formation via natural and synthetic molecules. | World J Microbiol Biotechnol | 2025 | https://conductscience.org/library/papers/40148661 | PubMed |
| 39360834 | Toward better cures for Mycobacterium abscessus lung disease. | Clin Microbiol Rev | 2024 | https://conductscience.org/library/papers/39360834 | PubMed |
| 38690364 | A laboratory perspective on Mycobacterium abscessus biofilm culture, characterization and drug activity testing. | Front Microbiol | 2024 | https://conductscience.org/library/papers/38690364 | PubMed |
| 38418662 | Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease. | Nat Rev Drug Discov | 2024 | https://conductscience.org/library/papers/38418662 | PubMed |
| 38380095 | Exploring antibiotic resistance mechanisms in Mycobacterium abscessus for enhanced therapeutic approaches. | Front Microbiol | 2024 | https://conductscience.org/library/papers/38380095 | PubMed |
| 37001025 | Synthesis and Characterization of Phenylalanine Amides Active against Mycobacterium abscessus and Other Mycobacteria. | J Med Chem | 2023 | https://conductscience.org/library/papers/37001025 | PubMed |
| 36222275 | Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance. | Angew Chem Int Ed Engl | 2022 | https://conductscience.org/library/papers/36222275 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36714853
GET https://conductscience.org/api/papers/v1/36714853/references?page=2